Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Assessing the safety of drugs for the long-term treatment of peptic ulcers.

× No keyword cloud information.

84 in total

Review 1. Chemical carcinogens and human risk assessment.

Authors: T C Campbell
Journal: Fed Proc Date: 1980-06

2. Dynamics of chronic gastritis in the remnant after partial gastrectomy for duodenal ulcer.

Authors: M Kekki; M Saukkonen; P Sipponen; K Varis; M Siurala
Journal: Scand J Gastroenterol Date: 1980 Impact factor: 2.423

3. Cimetidine: further evidence of noncarcinogenicity in dogs.

Authors: G P Crean; B C Morson; G B Leslie; F J Roe
Journal: N Engl J Med Date: 1981-03-12 Impact factor: 91.245

4. Does cimetidine play a "proinflammatory" role in fundic mucosa of duodenal ulcer patients?

Authors: A Giacosa; R Cheli; G Bertaccini; R Bocchini
Journal: Acta Gastroenterol Belg Date: 1980 May-Jun Impact factor: 1.316

5. Cimetidine is unlikely to increase formation of intragastric N-nitroso-compounds in patients taking a normal diet.

Authors: T J Muscroft; D J Youngs; D W Burdon; M R Keighley
Journal: Lancet Date: 1981-02-21 Impact factor: 79.321

Review 6. Overview of some aspects of quantitative risk assessment.

Authors: L Fishbein
Journal: J Toxicol Environ Health Date: 1980 Sep-Nov

7. Precancerous conditions and epithelial dysplasia in the stomach.

Authors: B C Morson; L H Sobin; E Grundmann; A Johansen; T Nagayo; A Serck-Hanssen
Journal: J Clin Pathol Date: 1980-08 Impact factor: 3.411

8. Epithelial proliferation in human fundic mucosa after antrectomy and vagotomy.

Authors: R T Assad; G L Eastwood
Journal: Gastroenterology Date: 1980-11 Impact factor: 22.682

9. Cimetidine treatment for the prevention of recurrence of duodenal ulcer: an international collaborative study.

Authors: W L Burland; B W Hawkins; J Beresford
Journal: Postgrad Med J Date: 1980-03 Impact factor: 2.401

10. Carcinogenicity of N-nitroso compounds. Species and route differences in regard to organotropism.

Authors: D Schmähl; M Habs
Journal: Oncology Date: 1980 Impact factor: 2.935

13 in total

1. U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

Authors: J E Valenzuela; R G Berlin; W J Snape; T L Johnson; B I Hirschowitz; J Colon-Pagan; R S Morse; J Petrozza; G M Van Deventer; A Cagliola
Journal: Dig Dis Sci Date: 1991-06 Impact factor: 3.199

Review 9. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors: S P Clissold; D M Campoli-Richards
Journal: Drugs Date: 1986-07 Impact factor: 9.546

10. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds.

Authors: E Verdu; F Viani; D Armstrong; R Fraser; H H Siegrist; B Pignatelli; J P Idström; C Cederberg; A L Blum; M Fried
Journal: Gut Date: 1994-04 Impact factor: 23.059

Assessing the safety of drugs for the long-term treatment of peptic ulcers.

Review 1. Chemical carcinogens and human risk assessment.

2. Dynamics of chronic gastritis in the remnant after partial gastrectomy for duodenal ulcer.

3. Cimetidine: further evidence of noncarcinogenicity in dogs.

4. Does cimetidine play a "proinflammatory" role in fundic mucosa of duodenal ulcer patients?

5. Cimetidine is unlikely to increase formation of intragastric N-nitroso-compounds in patients taking a normal diet.

Review 6. Overview of some aspects of quantitative risk assessment.

7. Precancerous conditions and epithelial dysplasia in the stomach.

8. Epithelial proliferation in human fundic mucosa after antrectomy and vagotomy.

9. Cimetidine treatment for the prevention of recurrence of duodenal ulcer: an international collaborative study.

10. Carcinogenicity of N-nitroso compounds. Species and route differences in regard to organotropism.

1. U.S. experience with omeprazole in duodenal ulcer. Multicenter double-blind comparative study with ranitidine. The Omeprazole DU Comparative Study Group.

Review 2. Histamine H2-receptor antagonists versus prostaglandins in the treatment of peptic ulcer disease.

3. Peptic ulcer disease. Pathophysiology and current medical management.

4. Gastric microflora.

5. Antisecretory drugs and gastric cancer.

Review 6. H2-receptor antagonists and gastric cancer.

7. Inhibition of human gastric secretion by ICI 162,846--a new histamine H2-receptor antagonist.

Review 8. Use of omeprazole in patients with Zollinger-Ellison syndrome.

Review 9. Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

10. Effect of omeprazole on intragastric bacterial counts, nitrates, nitrites, and N-nitroso compounds.